Literature DB >> 32430327

Reply to Hashimoto: Ketamine is not an opioid but requires opioid system for antidepressant actions.

Roberto Malinow1,2, Matthew E Klein3.   

Abstract

Entities:  

Year:  2020        PMID： 32430327      PMCID： PMC7260948          DOI： 10.1073/pnas.2002739117

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN： 0027-8424            Impact factor:   11.205


× No keyword cloud information.
  11 in total

1.  Association of Combined Naltrexone and Ketamine With Depressive Symptoms in a Case series of Patients With Depression and Alcohol Use Disorder.

Authors:  Gihyun Yoon; Ismene L Petrakis; John H Krystal
Journal:  JAMA Psychiatry       Date:  2019-03-01       Impact factor: 21.596

2.  Pharmacological inhibition of the lateral habenula improves depressive-like behavior in an animal model of treatment resistant depression.

Authors:  C Winter; B Vollmayr; A Djodari-Irani; J Klein; A Sartorius
Journal:  Behav Brain Res       Date:  2010-08-03       Impact factor: 3.332

Review 3.  Dextromethorphan/Bupropion: A Novel Oral NMDA (N-methyl-d-aspartate) Receptor Antagonist with Multimodal Activity.

Authors:  Stephen M Stahl
Journal:  CNS Spectr       Date:  2019-10       Impact factor: 3.790

Review 4.  Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms.

Authors:  Panos Zanos; Ruin Moaddel; Patrick J Morris; Lace M Riggs; Jaclyn N Highland; Polymnia Georgiou; Edna F R Pereira; Edson X Albuquerque; Craig J Thomas; Carlos A Zarate; Todd D Gould
Journal:  Pharmacol Rev       Date:  2018-07       Impact factor: 25.468

5.  Intravenous arketamine for treatment-resistant depression: open-label pilot study.

Authors:  Gustavo C Leal; Igor D Bandeira; Fernanda S Correia-Melo; Manuela Telles; Rodrigo P Mello; Flavia Vieira; Cassio S Lima; Ana Paula Jesus-Nunes; Lívia N F Guerreiro-Costa; Roberta F Marback; Ana Teresa Caliman-Fontes; Breno L S Marques; Marília L O Bezerra; Alberto L Dias-Neto; Samantha S Silva; Aline S Sampaio; Gerard Sanacora; Gustavo Turecki; Colleen Loo; Acioly L T Lacerda; Lucas C Quarantini
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2020-02-20       Impact factor: 5.270

6.  Are NMDA and opioid receptors involved in the antidepressant actions of ketamine?

Authors:  Kenji Hashimoto
Journal:  Proc Natl Acad Sci U S A       Date:  2020-05-19       Impact factor: 11.205

7.  Attenuation of Antidepressant Effects of Ketamine by Opioid Receptor Antagonism.

Authors:  Nolan R Williams; Boris D Heifets; Christine Blasey; Keith Sudheimer; Jaspreet Pannu; Heather Pankow; Jessica Hawkins; Justin Birnbaum; David M Lyons; Carolyn I Rodriguez; Alan F Schatzberg
Journal:  Am J Psychiatry       Date:  2018-08-29       Impact factor: 18.112

8.  The histidine triad nucleotide-binding protein 1 supports mu-opioid receptor-glutamate NMDA receptor cross-regulation.

Authors:  María Rodríguez-Muñoz; Pilar Sánchez-Blázquez; Ana Vicente-Sánchez; Concha Bailón; Beatriz Martín-Aznar; Javier Garzón
Journal:  Cell Mol Life Sci       Date:  2010-12-14       Impact factor: 9.261

9.  Opioid system is necessary but not sufficient for antidepressive actions of ketamine in rodents.

Authors:  Matthew E Klein; Joshua Chandra; Salma Sheriff; Roberto Malinow
Journal:  Proc Natl Acad Sci U S A       Date:  2020-01-15       Impact factor: 11.205

Review 10.  The Effect of a Single Dose of Intravenous Ketamine on Suicidal Ideation: A Systematic Review and Individual Participant Data Meta-Analysis.

Authors:  Samuel T Wilkinson; Elizabeth D Ballard; Michael H Bloch; Sanjay J Mathew; James W Murrough; Adriana Feder; Peter Sos; Gang Wang; Carlos A Zarate; Gerard Sanacora
Journal:  Am J Psychiatry       Date:  2017-10-03       Impact factor: 18.112
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.